Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- NMDA receptors in CNS glutamatergic synapse
- Origins of excitotoxicity research
- Loss of glutamate homeostasis
- NMDAR activity and Huntington's disease
- NMDAR activity and Alzheimer's disease
- NMDAR antagonists for excitotoxicity disorders?
- NMDAR activity and neuronal survival
- NMDAR activity and neuronal survival
- Physiological role of NMDAR for treating stroke
- Complete blockade of the NMDAR is not desirable
- Protective vs. toxic effects of NMDAR activity
- Trophic and protective effects of NMDAR
- Synaptic NMDAR activity and neuroprotection
- Synaptic activity induced gene expression
- Neuroprotection against apoptotic insults
- Transcriptional and post-translational events
- CREB and PI3K-Akt
- Genes whose regulation is most important
- Neuroprotection against oxidative insults
- Synaptic activity boosts antioxidant systems
- Neuroprotection against excitotoxic insults
- NMDAR activity and excitotoxic cell death
- NMDAR excitotoxicity involves several pathways
- What makes NMDAR activity toxic?
- Chronic activation of extrasynaptic NMDAR (1)
- Chronic activation of extrasynaptic NMDAR (2)
- NMDAR subunit composition
- Why subunit composition might influence toxicity?
- GluN2 C-terminus is linked to signaling proteins
- Chimeric constructs based on GluN2B and 2A
- Chimeric constructs have different excitotoxicity
- Alternative approach-analyse a mouse knock-in
- Knocked-in chimeric constructs (in vitro results)
- Knocked-in chimeric constructs (in vivo results)
- GluN2 CTD subtype and NO pro-death pathway
- Tat-NR2B9c
- Tat-NR2B9c in animal models of stroke
- Tat-NR2B9c in clinical trials
- Involvement of mitochondrial calcium uptake
- Mcu - mitochondrial calcium uniporter
- Knocking down endogenous Mcu expression
- Knocking down protects against cell death
- Current working model
- Summary
- Thank you
Topics Covered
- Excitotoxicity
- Historical background, implication of NMDA receptors and role in acute and chronic disorders
- Pro-survival signaling to gene expression from the NMDA receptor
- Mechanisms of excitotoxicity and role of receptor location and subunit composition
- Signaling to mitochondria in excitotoxicity
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Hardingham, G.E. (2014, April 7). NMDA receptors: neuroprotective or excitotoxic? [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/GWBN6638.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Giles E. Hardingham has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Neuroscience
Transcript
Please wait while the transcript is being prepared...
0:00
Hi.
My name is Giles Hardingham.
I work at the
University of Edinburgh.
And my laboratory is interested
in signal pathways and genes that
control the protection, as well
as the death and dysfunction,
of neurons.
Now, we're particularly interested
in calcium signalling pathways
and how calcium mediates
these kind of effects.
And one particular focus in the
lab is on an important source
of calcium influx, the NMDA subtype
of ionotrophic glutamate receptors.
0:33
So a typical glutamatergic
synapse, such as the one shown
in the cartoon here, the NMDA
receptor is a very important source
of activity-dependent
calcium influx.
What happens is you get
presynaptic release of glutamate
into the synaptic cleft, which
causes postsynaptic depolarization
mediated by the AMPA subtype
of glutamate receptor.
This postsynaptic
depolarization alleviates
the voltage-dependent magnesium
block on the NMDA receptor.
Which when, coincident with
glutamate binding to the receptor,
opens the channel and in flows
sodium, and importantly calcium.
And it's this calcium
that is a major mediator
of the neuroprotective, as well as
the toxic effects of NMDA receptor
activity.
1:22
So before going over more
contemporary research,
I just want to briefly outline
the origins of this field.
And the origins of the field,
the research into the control
of survival and death
by NMDA receptors
can be traced back
to a paper published
in 1957 by Lucas and Newhouse.
And what they observed was that
the amino acid glutamate, when
administered to the retina,
was toxic to the neurons
in the inner layers of the retina.
Now, this work wasn't followed
up until the late '60s, when
John Olney demonstrated
that glutamate could be
toxic to a wide variety of neurons
in different brain regions.
And he coined the term
"excitotoxity" because, of course,
glutamate by then was well known
as an excitatory neurotransmitter,
as well as being potentially toxic.
So it wasn't until the
mid-1980s that the major cause
of glutamate excitotoxity was pinned
down by Choi, Meldrum, and others
as being due to calcium
influx into the neurons.
And that this calcium influx was
mediated by the NMDA receptor,
the NMDA subtype of ionotrophic
glutamate receptors.
And extremely soon
afterwards, it became clear
that NMDA receptor-mediated
excitotoxity was physiologically
relevant because it was implicated
in contributing to neuronal loss
and dysfunction in acute
disorders, particularly
stroke and traumatic brain injury.
And later, it was implicated
in more chronic disorders,
such as Huntington's disease
and Alzheimer's, Abeta
toxicity as well.
So, of course, all this
happened before genes
encoding the NMDA
receptor were cloned.
At the time, researchers still
had pharmacological tools
that could isolate the currents
mediated by the NMDA receptor
and distinguish them from other
types of glutamate receptor,
like the AMPA and kainate receptor.
So the other thing I want to just
go over before we get into more
modern literature is how NMDA
receptor-mediated excitotoxicity
actually takes place.
And regardless of whether
the disorder is an acute one,
such as ischemia, or
a more chronic one,
such as Huntington's, it seems
that loss of glutamate homeostasis
is a key mediator.